Kula Investments’s Viridian Therapeutics VRDN Stock Holding History

Kula Investments’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,580	Closed	-$309K	–	868
2022 Q4	$309K	Buy	+10,580	New	+$244K	0.09%	381

Other funds holding VRDN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Kula Investments's VRDN Position: Q1 2023 in Review

Kula Investments sold out of Viridian Therapeutics (VRDN) in Q1 2023, closing a stake of 10,580 shares — an estimated $309K sold.

Kula Investments first reported a position in VRDN in Q4 2022 and held it in 1 quarter. The position peaked at $309K in Q4 2022. 135 funds tracked by Wall St. Rank hold VRDN as of Q1 2023.

Kula Investments reported no remaining Viridian Therapeutics position as of Q1 2023 after selling out during the quarter.
Kula Investments sold 10,580 Viridian Therapeutics shares in Q1 2023, an estimated $309K.
Kula Investments first reported a position in Viridian Therapeutics in Q4 2022 and held it in 1 quarter.
Kula Investments's Viridian Therapeutics position peaked at $309K in Q4 2022.
135 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.